Fig. 5: POLRMT depletion impedes prostate cancer cell viability, proliferation and migration. | Cell Death & Disease

Fig. 5: POLRMT depletion impedes prostate cancer cell viability, proliferation and migration.

From: Identification of the mitochondrial protein POLRMT as a potential therapeutic target of prostate cancer

Fig. 5

The primary pCan1 cells with the described genetic modification on POLRMT or the control genetic treatment (“shC+koC”) were established and cells were cultivated for the described time. Cell viability (CCK-8 assay) (A), death (by measuring Trypan blue-positive cells’ ratio) (B), proliferation (nuclear EdU incorporation) (C), and migration (“Transwell” assays) (D) were tested. The pCan2 primary prostate cancer cells and the immortalized lines (PC-3/LNCaP), with the lentiviral POLRMT shRNA (“shPOLRMT-S1”) or the lentiviral scramble control shRNA (“shC”), were established and cultivated for described time periods, cell viability (E), death (F), proliferation (G) and migration (H) were tested similarly, with results quantified. Data were presented as mean ± standard deviation (SD, n = 5). “Pare” stands for the parental control cells. *P < 0.05 vs. “shC+koC”/“shC” cells. The experiments were repeated five times with similar results obtained. Scale bar = 100 μm.

Back to article page